Cronos Group Inc.
CRON evidence brief
What we can confirm
- BioSniper Score:
- 6.6 / 10
- Market Cap:
- $1.18B
- Lead Asset:
- Spinach®
What it means
What to watch
Prepared research question
What matters most for CRON—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRON
Cronos Group Inc. (CRON) is a Canadian cannabis company focused on branded adult-use products, with a strong balance sheet and an expanding portfolio of edibles and vapes under its Spinach® brand.
Key risk: Regulatory uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.18B
Cash Runway
—
Lead Asset
Spinach®
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Cronos Group Inc..
Cronos Group Inc. (CRON) is a Canadian cannabis company focused on branded adult-use products, with a strong balance sheet and an expanding portfolio of edibles and vapes under its Spinach® brand.
- Cash & equivalents of $467.0M as of 2026-06-30 [sec]
- Net income of $32.1M as of 2026-06-30 [sec]
- Shareholders' equity of $1,068.7M as of 2026-06-30 [sec]
- Expanding its Spinach® brand lineup with new edibles and vape flavors in 2026 [news · 2026-09-02]
- Recognized as one of the leaders in a selective cannabis recovery, with strong balance sheets and clinical pipelines [news · 2026-08-29]
What works
- Strong cash position of $467.0M as of 2026-06-30 provides liquidity for operations, acquisitions, and share repurchases [sec]
- Positive net income of $32.1M as of 2026-06-30 indicates profitability [sec]
- Brand Spinach® is expanding its best-selling edibles and vapes lineups, suggesting product-market traction [news · 2026-09-02]
- Described as a leader in a selective cannabis recovery, with a strong balance sheet [news · 2026-08-29]
What to weigh
- Forward-looking statements are subject to risks and uncertainties, and are not guarantees of future performance [sec · filed 2026-04-24]
- Potential adverse effects from judicial, regulatory, or other proceedings, including uncertainty regarding U.S. federal and state cannabis laws [sec_mda · as of 2026-08-06]
- Risk of insufficient cash flow or liquidity to execute the business plan or fund capital expenditures [sec_mda · as of 2026-08-06]
- Competitive landscape includes other cannabis companies and clinical trials for cannabis withdrawal treatments [competitor_trial]
Risks & what to watch (3)›
Key risks
- Regulatory uncertainty — Uncertainty regarding U.S. state and federal law application to cannabis and hemp products [sec_mda · as of 2026-08-06]
- Cash flow risk — Risk of insufficient cash flow or liquidity to execute business plan or fund capital expenditures [sec_mda · as of 2026-08-06]
- Forward-looking statement risk — Forward-looking statements are not guarantees of future performance and are subject to risks and assumptions [sec · filed 2026-04-24]
What to watch
- Third quarter 2026 earnings conference call scheduled for November 5, 2026 [news · published 2026-10-08]
- Execution of the renewed share repurchase program authorized on May 8, 2026 [sec_mda · as of 2026-08-06]
- Completion of the agreement to acquire CanAdelaar B.V. and integration of that business [sec_mda · as of 2026-08-06]
- Performance of the High Tide Loan and High Tide Warrant [sec_mda · as of 2026-08-06]
Sources: Catalysts · Competitor trials · News · Pipeline · SEC filings · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run Cronos Group Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cronos Group Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
No tracked pipeline phase
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 21, 2026- % of float
- 2.0%
- Days to cover
- 3.7
- Shares short
- 3,828,177
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRON short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cronos Group Inc.?
Cronos Group Inc. (CRON) is a Canadian cannabis company focused on branded adult-use products, with a strong balance sheet and an expanding portfolio of edibles and vapes under its Spinach® brand.
Who is the CEO of Cronos Group Inc.?
Mr. Michael Ryan Gorenstein J.D. is the chief executive officer of Cronos Group Inc. (CRON).
Where is Cronos Group Inc. headquartered?
Cronos Group Inc. (CRON) is headquartered in Stayner, ON, Canada.
What therapeutic areas does Cronos Group Inc. focus on?
Cronos Group Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.